Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHERYL A HULL

Allopathic & Osteopathic Physicians Dermatology

NPI
1124081849
CMS profile
142103
Location
ROGERS, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,474.67

21 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHERYL A HULL

NPI 1124081849 · CMS profile ID 142103

Allopathic & Osteopathic Physicians / Dermatology

ROGERS, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124081849?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHERYL A HULL, NPI 1124081849, CMS profile ID 142103. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124081849?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). CHERYL A HULL, NPI 1124081849, CMS profile ID 142103. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124081849?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
CHERYL A HULL, NPI 1124081849, CMS profile ID 142103, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1124081849?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

21 matching records · $1,474.67 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 21 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–21 of 21.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $163.4012/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997516927 CMS
ABBVIE INC. $18.1011/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997516925 CMS
ABBVIE INC. $25.7311/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997516923 CMS
Arcutis Biotherapeutics, Inc. $19.1010/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044670603 CMS
ABBVIE INC. $6.7410/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997516921 CMS
ABBVIE INC. $15.5310/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997516919 CMS
Arcutis Biotherapeutics, Inc. $825.0010/03/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044670591 CMS
ABBVIE INC. $23.5309/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997516917 CMS
ABBVIE INC. $27.9309/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997516915 CMS
Regeneron Healthcare Solutions, Inc. $20.3909/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999218177 CMS
ABBVIE INC. $10.1408/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997516913 CMS
Sun Pharmaceutical Industries Inc. $31.9308/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053814193 CMS
Sun Pharmaceutical Industries Inc. $23.1507/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053814197 CMS
ABBVIE INC. $18.6407/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997516911 CMS
Dermavant Sciences, Inc. $109.5106/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991203331 CMS
Sun Pharmaceutical Industries Inc. $24.3605/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053814189 CMS
ABBVIE INC. $26.3604/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997516909 CMS
ABBVIE INC. $21.4402/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997516907 CMS
Organogenesis Inc. $31.1702/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048113263 CMS
STRATA Skin Sciences, Inc. $12.9202/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052694705 CMS
Allergan, Inc. $19.6001/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 973113691 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,430.05 27
PY2020 $231.11 11
PY2021 $627.01 26
PY2022 $517.89 25
PY2023 $1,474.67 21
PY2024 $880.69 32
PY2025 $676.63 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $380,038.55 259
PY2024 Principal investigator $408,860.46 382
PY2023 Principal investigator $228,849.11 170
PY2022 Recipient $321.00 1
PY2022 Principal investigator $248,165.36 66
PY2021 Recipient $2,700.00 2
PY2021 Principal investigator $244,500.15 37
PY2020 Recipient $643.47 2
PY2020 Principal investigator $251,307.20 46
PY2019 Recipient $4.75 1
PY2019 Principal investigator $990,287.65 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $6,000.00 12/17/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
PHASE 1, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, TRIPLE-BLIND, SINGLE-ASCENDING DOSE AND REPEAT-DOSE TRIAL IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 728737055
Principal investigator 1 Bausch Health US, LLC $900.00 12/10/2020 Non-covered Recipient Individual A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-120 GEL AND IDP-120 VEHICLE IN THE TREATMENT OF ACNE VULAGRIS No dispute reported 06/30/2026 737375451
Principal investigator 1 AbbVie Inc. $1,558.20 11/30/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
M15-997 No dispute reported 06/30/2026 721197685
Principal investigator 1 AbbVie Inc. $178.80 11/19/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
M15-999 No dispute reported 06/30/2026 721196289
Principal investigator 1 Bausch Health US, LLC $6,300.00 11/13/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737375355
Principal investigator 1 AbbVie Inc. $6,000.00 10/27/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
M15-999 No dispute reported 06/30/2026 721192231
Principal investigator 1 Eli Lilly and Company $3,500.00 10/26/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 728746955
Principal investigator 1 Novartis Pharmaceuticals Corporation $774.00 10/15/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EXTENSION STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE LONG-TERM EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 753932520
Principal investigator 1 Bausch Health US, LLC $6,215.00 10/05/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737375243
Principal investigator 1 Incyte Corporation $4,071.60 09/25/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations No dispute reported 06/30/2026 744298537
Principal investigator 1 Janssen Research & Development, LLC $1,920.60 09/24/2020 Non-covered Recipient Entity
Nw Arkansas Clnc Trials Ctr Pllc
A multicenter open registry of patients with psoriasis who are candidates for systematic therapy including biologics No dispute reported 06/30/2026 719511409
Recipient Eli Lilly and Company $293.47 09/10/2020 Covered Recipient Physician A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 728718485
Principal investigator 1 Bausch Health US, LLC $9,310.00 09/08/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737375149
Principal investigator 1 VYNE Pharmaceuticals Inc. $5,820.54 09/03/2020 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
FX2016-40 No dispute reported 06/30/2026 753087791
Principal investigator 1 AbbVie Inc. $1,745.40 08/28/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
M15-997 No dispute reported 06/30/2026 721183759
Principal investigator 1 Galderma Research & Development, LLC $2,500.00 08/28/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO COMPARE EFFICACY AND SAFETY OF TRIFAROTENE (CD5789) CREAM WHEN USED WITH AN ORAL ANTIBIOTIC FOR THE TREATMENT OF SEVERE ACNE VULGARIS No dispute reported 06/30/2026 725256889
Recipient Eli Lilly and Company $350.00 08/18/2020 Covered Recipient Physician PHASE 1, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, TRIPLE-BLIND, SINGLE-ASCENDING DOSE AND REPEAT-DOSE TRIAL IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 728718163
Principal investigator 1 AbbVie Inc. $1,710.60 07/30/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
M15-997 No dispute reported 06/30/2026 721178423
Principal investigator 1 Janssen Research & Development, LLC $1,884.60 07/29/2020 Non-covered Recipient Entity
Nw Arkansas Clnc Trials Ctr Pllc
A multicenter open registry of patients with psoriasis who are candidates for systematic therapy including biologics No dispute reported 06/30/2026 719511406
Principal investigator 1 Bausch Health US, LLC $1,340.00 07/24/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737374855
Principal investigator 1 AbbVie Inc. $1,290.00 07/15/2020 Non-covered Recipient Entity
HULL DERMATOLOGY AND AESTHETICS
P10-023 No dispute reported 06/30/2026 721175971
Principal investigator 1 Bausch Health US, LLC $400.00 07/13/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737374805
Principal investigator 1 Bausch Health US, LLC $200.00 07/13/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737374809
Principal investigator 1 AbbVie Inc. $3,126.00 07/01/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
M15-997 No dispute reported 06/30/2026 721174223
Principal investigator 1 Bausch Health US, LLC $3,000.00 06/08/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737374677
Principal investigator 1 VYNE Pharmaceuticals Inc. $8,661.60 05/28/2020 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
FX2016-40 No dispute reported 06/30/2026 753087801
Principal investigator 1 AbbVie Inc. $1,646.20 05/21/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
M15-999 No dispute reported 06/30/2026 721166669
Principal investigator 1 Eli Lilly and Company $43.50 05/08/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 728746957
Principal investigator 1 AbbVie Inc. $1,345.80 04/30/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
M15-997 No dispute reported 06/30/2026 721164253
Principal investigator 1 Bausch Health US, LLC $3,000.00 04/30/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737374045
Principal investigator 1 AbbVie Inc. $9,500.00 04/29/2020 Non-covered Recipient Entity
INLAND RHEUMLGY CLINICAL TRIALS INC
M19-944 No dispute reported 06/30/2026 721162797
Principal investigator 1 AbbVie Inc. $1,380.60 03/30/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
M15-997 No dispute reported 06/30/2026 721158883
Principal investigator 1 Bausch Health US, LLC $2,352.00 03/19/2020 Non-covered Recipient Individual A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-120 GEL AND IDP-120 VEHICLE IN THE TREATMENT OF ACNE VULAGRIS No dispute reported 06/30/2026 737373831
Principal investigator 1 VYNE Pharmaceuticals Inc. $10,412.15 03/13/2020 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
FX2016-40 No dispute reported 06/30/2026 753087797
Principal investigator 1 AbbVie Inc. $2,097.60 02/28/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
M15-997 No dispute reported 06/30/2026 721153737
Principal investigator 1 AbbVie Inc. $1,648.20 02/20/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
M15-999 No dispute reported 06/30/2026 721151483
Principal investigator 1 DERMIRA, INC. $6,650.00 02/20/2020 Non-covered Recipient Entity
NW ARKANSAS CLINICAL TRIALS CTR PLLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 736909219
Principal investigator 1 Bausch Health US, LLC $8,043.00 02/17/2020 Non-covered Recipient Individual A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-120 GEL AND IDP-120 VEHICLE IN THE TREATMENT OF ACNE VULAGRIS No dispute reported 06/30/2026 737373435
Principal investigator 1 VYNE Pharmaceuticals Inc. $9,382.48 02/10/2020 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center PLLC
FX2016-40 No dispute reported 06/30/2026 753087793
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,110.88 02/04/2020 Non-covered Recipient Entity
Dr Cheryl Hull
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 736759673
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $17,217.42 02/04/2020 Non-covered Recipient Entity
Dr Cheryl Hull
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis No dispute reported 06/30/2026 736759675
Principal investigator 1 Incyte Corporation $1,479.60 02/03/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations No dispute reported 06/30/2026 744298467
Principal investigator 1 AbbVie Inc. $1,066.20 01/30/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
M15-997 No dispute reported 06/30/2026 721148567
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,120.63 01/15/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF SUBCUTANEOUS SECUKINUMAB IN SUBJECTS OF BODY WEIGHT 90 KG OR HIGHER WITH MODERATE TO SEVERE CHRONIC PLAQUE TYPE PSORIASIS No dispute reported 06/30/2026 721494075
Principal investigator 1 Novartis Pharmaceuticals Corporation $58,838.92 01/15/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A RANDOMIZED DOUBLE BLIND MULTI CENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF 2 SUBCUTANEOUS SECUKINUMAB DOSE REGIMENS IN ADULT PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA SUNSHINE No dispute reported 06/30/2026 721494077
Principal investigator 1 Amgen Inc. $77.44 01/08/2020 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER, PLLC / HULL DERMATOLOGY
A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp (STYLE) No dispute reported 06/30/2026 731625095
Principal investigator 1 Celgene Corporation $77.44 01/08/2020 Non-covered Recipient Entity
Hull Dermatology And Aesthetics
A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY OF THE EFFICACY AND SAFETY Of APREMILAST (CC-10004), COMPARED TO PLACEBO, IN SUBJECTS WTIH MILD TO MODERATE PLAQUE PSORIASIS No dispute reported 06/30/2026 736446921
Principal investigator 1 Amgen Inc. $14,410.20 01/07/2020 Non-covered Recipient Entity
HULL DERMATOLOGY, NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
Efficacy/Safety study of Apremilast in subjects with Mild-to-moderate Plaque Psoriasis (PSOR-022) No dispute reported 06/30/2026 731627409